TempraMed Technologies Ltd. News Releases

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Thu, 04 Jun 2026 07:00:00 -0400

Expands Latin America presence with strategic partnership with Mobil Saúde and builds on TempraMed's recently granted Brazilian patent portfolio HighlightsTempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world's largest markets for diabetes, GLP-1 therapies, and temperature-sensitive biologics1. Diabetes market alone reached USD $2.15 Billion in 2025 Partnership builds on TempraMed's recently granted Brazilian patent...

TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications

Fri, 22 May 2026 11:57:00 -0400

Broadcast across the United States brings attention to the under-addressed risk of medication degradation caused by heat exposure and the real-world need for better medication protection and tracking Vancouver, British Columbia--(Newsfile Corp. - May 22, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed a medical technology innovator transforming how...

TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product

Thu, 14 May 2026 03:00:00 -0400

Another major milestone in its continuous global IP strategy, advancing protection of VIVI Cap Smart across international markets HighlightsGranted Patent covers the design of VIVI Cap Smart™ across major international, growing marketStrengthens the Company's intellectual property position in one of the world's largest healthcare and consumer marketsSupports commercialization strategy and strategic discussions with appliance manufacturers Design term extends through May 16, 2039Company enters...

TempraMed Announces Continuance into Ontario

Wed, 29 Apr 2026 16:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has continued out of the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) into the provincial jurisdiction of Ontario under the Business Corporations Act (Ontario)...

TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product

Tue, 07 Apr 2026 07:00:00 -0400

Grant in Brazil marks a major milestone in global IP strategy, advancing protection of its VIVI Box across key international markets HighlightsBrazilian patent officially granted by the Brazilian Patent Office Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer marketsSupports commercialization strategy and strategic...

TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure

Mon, 30 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI"), dated March 22, 2026, with TEM Consulting International S.A. ("TEM") a leading healthcare logistics and consultancy company based in the Panama, with respect to the...

TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box

Tue, 24 Mar 2026 07:00:00 -0400

Grant in China marks a major milestone in global IP strategy, advancing protection of its VIVI Box platform across key international markets HighlightsChinese patent officially granted by CNIPA on March 17, 2026Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer marketsSupports commercialization strategy and...

TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap

Wed, 11 Mar 2026 07:00:00 -0400

Peer-reviewed case report by Prof. Andreas Pfützner demonstrates real-world insulin protection during extreme heat exposure and aligns with previously validated savings model Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating...

TempraMed Reports over 275 Clinicians Recommending VIVI Cap to Patients on Leading FrontrowMD Platform Across the United States

Thu, 26 Feb 2026 07:00:00 -0500

Partnership results in over 275 physicians recommending VIVI Cap to patients, strengthening clinical validation and driving scalable patient education and acquisition Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that more than 275 physicians across the United...

TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy

Tue, 10 Feb 2026 03:00:00 -0500

Super-Pharm operates nationwide, serving millions of consumers annually Vancouver, British Columbia--(Newsfile Corp. - February 10, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super-Pharm, Israel's largest and most prominent pharmacy and health-retail chain, operating nationwide and...